Liquidia Corporation
LQDA
$-0.06
Change (1 day)
$16.99
Year High
$5.71
Year Low
Categories
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Earnings for Liquidia Corporation (LQDA)
Earnings in 2023 (TTM): $-78,502,000
According to Liquidia Corporation's latest financial reports the company's current earnings (TTM) are $-78,502,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Liquidia Corporation
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-78,502,000 | $-78,502,000 |
| 2022 | $-41,015,000 | $-38,365,000 |
| 2021 | $-34,578,648 | $-29,781,809 |
| 2020 | $-59,762,769 | $-57,491,188 |
| 2019 | $-47,583,455 | $-46,389,335 |
| 2018 | $-53,135,859 | $-53,135,859 |
| 2017 | $-29,154,240 | $-29,154,240 |
| 2016 | $-15,933,762 | $-15,933,762 |